• Alias: BAY 80-6946
    • An orally potent, highly selective, reversible pan-class I PI3K inhibitor
    • FDA approved in September 2017 for relapsed follicular lymphoma
    • Recommended dose: 60 mg IV over 1 hour every week for 3 weeks, 1 week off of a 28-day cycle
    • Metabolism: Avoid concomitant use of potent CYP3A4 inhibitors. If it cannot be avoided, decrease the dose of copanlisib to 45 mg.
    • Half-life: 39.1 hours (range 14.6–82.4 hours)
    • Common side effects: Hyperglycemia, nausea/diarrhea, mucositis, fatigue, hypertension, skin rash, hypertriglyceridemia, hypophosphatemia
    Other topics in Targeted and Immunotherapy Agents